长江生命科技(00775.HK) 公布，旗下全资附属公司Sealbond Limited (Sealbond)与纳斯达克上市生物科技公司Virios Therapeutics, Inc. (VIRI)达成协议。据悉，VIRI将从Sealbond收购WEX Pharmaceuticals Inc. (WEX)的母公司，而Sealbond则获取VIRI股权。交易完成后，合并公司将改名为Dogwood Therapeutics, Inc. (Nasdaq股份代号：DWTX)，并维持纳斯达克证券交易所上巿地位。
Virios Therapeutics, Inc.将发行价值1亿美元(折合约7.8亿港元)之新股以收购WEX的母公司。有关新股将包括VIRI之普通股及一系列没有投票权之新优先股，该等优先股可于VIRI股东批准后，以及符合Nasdaq相关规例和法规的条件下转换为普通股。紧随交易完成后，长江生命科技将透过Sealbond持有VIRI约15.9%的已发行普通股。于优先股转换为普通股后，长江生命科技将透过Sealbond持有VIRI约90.7%的已发行普通股。
长江生命科技亦同意，透过全资附属公司以贷款形式提供达1,950万美元(约1.52亿港元)之策略性融资，以加快WEX发展临床及研发活动。
长江生命科技副主席及执行董事余英才表示，WEX与VIRI合并乃长江生命科技的一个策略性发展里程碑。是次合并有利WEX于美国资本市场进行融资及壮大研发团队，加快WEX的开发。(js/w)
(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.